Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15810876 | 1.00 | CHRM2 (0.55) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL23245840 | 1.00 | CHRM2 (0.55) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL18403419 | 1.00 | CHRM2 (0.55) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL23245486 | 1.00 | CHRM2 (0.55) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL14110948 | 0.82 | SMN1; SMN2 (0.53) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL12853549 | 0.81 | SMN1; SMN2 (0.42) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL24904052 | 0.80 | CHRM2 (0.38) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL22801499 | 0.79 | SMN1; SMN2 (0.40) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL13051086 | 0.79 | SMN1; SMN2 (0.40) | CHRM2CHRM1CHRM3LMNACYP2C9 | |
| SCHEMBL744650 | 0.79 | SMN1; SMN2 (0.40) | CHRM2CHRM1CHRM3LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961256-B2 | PRMT5 inhibitors | CTXT PTY LTD (AU) | 2021-03-30 | — | — | US | disclosed |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2019-09-24 | — | — | US | disclosed |
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2019-03-07 | — | — | US | disclosed |
| US-10005792-B2 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | CTXT PTY. LTD. (AU) | 2018-06-26 | — | — | US | disclosed |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-11-02 | — | — | US | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-05 | — | — | US | disclosed |
| WO-2017153518-A1 | PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153513-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153515-A1 | TETRAHYDROISOQUINOLINES AS PRMT5-INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034675-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034671-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
| US-20150203494-A1 | PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS | PURDUE PHARMA L.P. | 2015-07-23 | — | — | US | disclosed |
| US-20150183787-A1 | PROPELLANE-BASED COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2015-07-02 | — | — | US | disclosed |
| WO-2015097546-A1 | PROPELLANE-BASED COMPOUNDS AND THEIR USE AS OPIOID RECEPTOR MODULATORS | PURDUE PHARMA L.P. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-8980906-B2 | Pyridonemorphinan analogs and biological activity on opioid receptors | PURDUE PHARMA L.P. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140187549-A1 | Pyridonemorphinan Analogs and Biological Activity on Opioid Receptors | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2014091295-A1 | PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS | PURDUE PHARMA L.P. (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005792-B2 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | PRMT5, PRMT1, PRMT3 | CHRM2 744/4885CHRM1 518/4885CHRM3 1226/4885 |
| US-20150183787-A1 | PROPELLANE-BASED COMPOUNDS AND THE USE THEREOF | OPRL1, OPRK1, OPRD1 | CHRM2 201/4885CHRM1 65/4885CHRM3 170/4885 |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | CHRM2 764/4885CHRM1 500/4885CHRM3 1194/4885 |
| US-20140187549-A1 | Pyridonemorphinan Analogs and Biological Activity on Opioid Receptors | OPRM1, OPRK1, OPRL1 | CHRM2 23/4885CHRM1 9/4885CHRM3 26/4885 |
| US-20150203494-A1 | PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS | OPRM1, OPRK1, OPRL1 | CHRM2 24/4885CHRM1 9/4885CHRM3 25/4885 |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | CHRM2 1019/4885CHRM1 518/4885CHRM3 1779/4885 |
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | CHRM2 459/4885CHRM1 163/4885CHRM3 648/4885 |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | CHRM2 459/4885CHRM1 163/4885CHRM3 648/4885 |
| US-10961256-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | CHRM2 726/4885CHRM1 288/4885CHRM3 1280/4885 |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT3, PRMT1 | CHRM2 980/4885CHRM1 682/4885CHRM3 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.